LKT Labs

Biochemicals for Life Science Research

MLN8237

MLN8237

Product ID M4652
Cas No. 1028486-01-2
Purity ≥98%
Product Unit SizeCostQuantityStock
1 mg $118.00 In stock
5 mg $219.00 In stock
10 mg $337.00 In stock
Bulk Quote

Quicklinks

Description

MLN8237 inhibits aurora kinase A (AurA) preventing mitotic spindle formation and proper completion of mitosis. MLN8237 exhibits anticancer chemotherapeutic activity and is currently in clinical trials as a potential treatment for multiple myeloma, non-Hodgkin’s lymphoma, and chronic lymphocytic leukemia (CLL). In bladder cancer cells, MLN8237 induces cell cycle arrest, aneuploidy, and apoptosis; in animal models of bladder cancer, this compound inhibits tumor growth. Additionally, MLN8237 inhibits tumor growth of neuroblastomas in vivo as well. In HUVECs, MLN8237 decreases tubule formation and inhibits VEGF secretion, suggesting potential anti-angiogenic activity.

Product Info

Cas No.

1028486-01-2
Purity

≥98%
Formula

C27H20ClFN4O4
Formula Wt.

518.92
IUPAC Name

4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid
Synonym

Alisertib
Solubility

DMSO 27 mg/mL (52.03 mM) Water Insoluble Ethanol Insoluble
Appearance

Pale Yellow Powder

Shipping and Storage

Store Temp

-20°C
Ship Temp

Ambient

Downloads

MSDS

M4652 MSDS PDF
Info Sheet

M4652 Info Sheet PDF

References

Romain C, Paul P, Kim KW, et al. Targeting Aurora kinase-A downregulates cell proliferation and angiogenesis in neuroblastoma. J Pediatr Surg. 2014 Jan;49(1):159-65. PMID: 24439602.

Kelly KR, Shea TC, Goy A, et al. Phase I study of MLN8237-investigational Aurora A kinase inhibitor-in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia. Invest New Drugs. 2013 Dec 20. [Epub ahead of print]. PMID: 24352795.

Zhou N, Singh K, Mir MC, et al. The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo. Clin Cancer Res. 2013 Apr 1;19(7):1717-28. PMID: 23403633.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • G7440

    GSK-1120212

    MEK1/2 inhibitor.

    ≥98%
  • A121008

    Adagrasib

    KRAS inhibitor

    ≥99%
  • R5212

    RN-486

    Btk inhibitor.

    ≥98%
  • S0049

    Salmon Calcitonin Acetate

    Peptide, involved in feeding behavior and insul...

    ≥95%
  • E0001

    E64

    Cysteine protease inhibitor.

    ≥99%
  • C9879

    Cytochalasin B

    Mycotoxin produced by Aspergillus; actin polyme...

    ≥98%
  • L5769

    Lorglumide Sodium

    CCK antagonist.

    ≥98%
  • H8162

    (−)-Huperzine A

    Sesquiterpene alkaloid found in Huperzia serrat...

    ≥97%
  • E5210

    Endomorphin-1

    Endogenous opioid peptide; μOr agonist.

    ≥95%
  • C2945

    Chlorophyllin Sodium-Copper Salt

    Semi-synthetic derivative of chlorophyll; food ...

    USP 28
  • N8663

    NVP-LDE225 Diphosphate

    Smo inhibitor.

    ≥98%
  • V182685

    Verdinexor

    CRM1/XPO1 inhibitor.

    ≥99%
  • D3232

    3,3′-Diindolylmethane

    Indole found in cruciferous vegetables; AhR ago...

    ≥98%
  • E5214

    α-Endorphin

    Endogenous opioid peptide; μOR agonist.

    ≥95%
  • A2532

    AGI-6780

    Isocitrate dehydrogenase inhibitor.

    ≥98%
  • L1044

    LCL-161

    SMAC mimetic; PXR agonist, IAP inhibitor.

    ≥99%, ≥99%ee, de
  • C0221

    Caffeine

    Xanthine alkaloid found in coffee, tea, and oth...

    ≥98%
  • G124080

    GDC-0994

    ERK1/2 inhibitor.

    ≥98%
  • Z3463

    Ziprasidone

    5-HT1A agonist, D2, 5-HT1D antagonist.

    ≥98%
  • N0205

    Nabumetone

    1-Naphthalenacetic acid derivative, NSAID; COX-...

    ≥98%